CN105008333B - N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途 - Google Patents

N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途 Download PDF

Info

Publication number
CN105008333B
CN105008333B CN201380068524.8A CN201380068524A CN105008333B CN 105008333 B CN105008333 B CN 105008333B CN 201380068524 A CN201380068524 A CN 201380068524A CN 105008333 B CN105008333 B CN 105008333B
Authority
CN
China
Prior art keywords
propyl
disease
sulfate
diisobutylamino
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380068524.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105008333A (zh
Inventor
S·比莱
C·埃斯特瑞拉
M·巴里尔
P·梅尔尼克
N·塞格安特
L·比埃
P·韦瓦尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALZPROTECT
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Original Assignee
National Medical And Health Research Institute
ALZPROTECT
Universite Lille 2 Droit et Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Medical And Health Research Institute, ALZPROTECT, Universite Lille 2 Droit et Sante filed Critical National Medical And Health Research Institute
Publication of CN105008333A publication Critical patent/CN105008333A/zh
Application granted granted Critical
Publication of CN105008333B publication Critical patent/CN105008333B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380068524.8A 2012-12-27 2013-12-27 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途 Active CN105008333B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP12306690.4 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
CN105008333A CN105008333A (zh) 2015-10-28
CN105008333B true CN105008333B (zh) 2018-02-09

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380068524.8A Active CN105008333B (zh) 2012-12-27 2013-12-27 N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途

Country Status (23)

Country Link
US (3) US9562018B2 (https=)
EP (1) EP2938597B1 (https=)
JP (1) JP6384923B2 (https=)
KR (1) KR102115060B1 (https=)
CN (1) CN105008333B (https=)
AU (2) AU2013369288B2 (https=)
BR (1) BR112015015474B1 (https=)
CA (1) CA2895285C (https=)
DK (1) DK2938597T3 (https=)
ES (1) ES2605494T3 (https=)
HR (1) HRP20161612T2 (https=)
HU (1) HUE030930T2 (https=)
IL (1) IL239450B (https=)
LT (1) LT2938597T (https=)
MX (1) MX363367B (https=)
NZ (1) NZ708959A (https=)
PL (1) PL2938597T3 (https=)
PT (1) PT2938597T (https=)
RS (1) RS55511B1 (https=)
RU (1) RU2655454C2 (https=)
SI (1) SI2938597T1 (https=)
WO (1) WO2014102339A1 (https=)
ZA (1) ZA201504521B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2938597T (lt) 2012-12-27 2017-01-25 Alzprotect N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
JP2023543630A (ja) * 2020-10-01 2023-10-17 アルツプロテクト Ｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミンのコハク酸塩、それらの調製及びそれらの使用
US20230364076A1 (en) * 2020-10-07 2023-11-16 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
CN118524838A (zh) 2021-12-20 2024-08-20 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺琥珀酸盐及其溶剂合物用于治疗运动神经元疾病和神经肌肉接头病症的用途
CN118946356A (zh) 2022-03-25 2024-11-12 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的盐及其溶剂化物用于治疗感觉神经元疾病的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
US20050020582A1 (en) * 2001-05-25 2005-01-27 Prusiner Stanley B Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
ATE524181T1 (de) * 2004-11-10 2011-09-15 Inst Nat Sante Rech Med Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
LT2938597T (lt) * 2012-12-27 2017-01-25 Alzprotect N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas

Also Published As

Publication number Publication date
AU2013369288A1 (en) 2015-07-02
RS55511B1 (sr) 2017-05-31
CA2895285C (en) 2021-03-30
HUE030930T2 (hu) 2017-06-28
CN105008333A (zh) 2015-10-28
BR112015015474A2 (https=) 2017-08-15
DK2938597T3 (en) 2017-01-09
US10772884B2 (en) 2020-09-15
RU2655454C2 (ru) 2018-05-29
JP2016503813A (ja) 2016-02-08
US9562018B2 (en) 2017-02-07
HRP20161612T1 (hr) 2017-01-27
ES2605494T3 (es) 2017-03-14
RU2015130671A (ru) 2017-01-30
SI2938597T1 (sl) 2017-03-31
NZ708959A (en) 2019-11-29
EP2938597A1 (en) 2015-11-04
ZA201504521B (en) 2016-11-30
AU2018202218B2 (en) 2019-02-21
AU2013369288A8 (en) 2015-07-16
US20170151235A1 (en) 2017-06-01
IL239450B (en) 2018-06-28
JP6384923B2 (ja) 2018-09-05
LT2938597T (lt) 2017-01-25
US20160108003A1 (en) 2016-04-21
WO2014102339A1 (en) 2014-07-03
MX2015008502A (es) 2015-12-16
PT2938597T (pt) 2016-12-09
CA2895285A1 (en) 2014-07-03
MX363367B (es) 2019-03-20
AU2018202218A1 (en) 2018-04-26
KR20150105313A (ko) 2015-09-16
IL239450A0 (en) 2015-07-30
BR112015015474B1 (pt) 2022-04-19
AU2013369288B2 (en) 2018-02-22
US20190381036A1 (en) 2019-12-19
HK1215582A1 (en) 2016-09-02
US10537569B2 (en) 2020-01-21
KR102115060B1 (ko) 2020-05-25
EP2938597B1 (en) 2016-10-26
HRP20161612T2 (hr) 2017-02-24
PL2938597T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
CN105008333B (zh) N‑(3‑(4‑(3‑(二异丁基氨基)丙基)哌嗪‑1‑基)丙基)‑1H‑苯并[d]咪唑‑2‑胺的硫酸盐、其制备及其用途
AU2020204164B2 (en) Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US10723730B2 (en) Solid forms of a selective CDK4/6 inhibitor
SG185594A1 (en) A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2013134371A1 (en) Methods and compounds to be used in the treatment of neurodegenerative diseases
JP2024056724A (ja) ムスカリン性アセチルコリン受容体アゴニストの結晶性多形
JP2025085656A (ja) Ｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミンのコハク酸塩、それらの調製及びそれらの使用
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
HK1215582B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
WO2026023672A1 (ja) （２Ｒ）－Ｎ－ベンジル－１－［５－（２－フルオロプロパン－２－イル）－７－オキソ－６，７－ジヒドロ［１，３］チアゾロ［５，４－ｄ］ピリミジン－２－イル］ピロリジン－２－カルボキサミドの新規結晶、およびその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20230201

Address after: French Ross

Patentee after: ALZPROTECT

Patentee after: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Patentee after: UNIVERSITE DE LILLE

Address before: French Ross

Patentee before: ALZPROTECT

Patentee before: INSERM (INSTITUT NATIONAL DE LA SANTe ET DE LA RECHERCHE MeDICALE)

Patentee before: University LILLE II DROIT & SANTE

TR01 Transfer of patent right